Top

Published in:

01-12-2016 | Original Article

Evaluation of serum immunoglobulins concentrations and distributions in vitiligo patients

Authors: Yulong Li, Min Yang, Rui Zhang, Wan Liu, Kuo Zhang, Wei Wen, Lang Yi, Qiaoxian Wang, Mingju Hao, Hui Yang, Jianmin Chang, Jinming Li

Published in: Immunologic Research | Issue 5-6/2016

Abstract

Vitiligo is a dermatological disorder with an autoimmune mechanism characterized by production of a variety of autoantibodies. Different levels of immunoglobulins can indicate the presence and the stage of some autoimmune diseases. We aimed to investigate serum IgA, IgM and IgG subclass levels and melanocyte-reactive antibodies in 65 vitiligo patients by the immunonephelometric assay (35 healthy people as controls). Compared with normal controls, a significant increase in total IgG, IgG1 and IgG2 (p = .005, p = .003 and p = .043, respectively) was observed in progressive nonsegmental vitiligo patients. Also, we found a significant decrease in IgG3 (p = .000 and p = .023) in progressive nonsegmental vitiligo patients and segmental patients. Moreover, we found the serum levels of IgG4 subclass in stable nonsegmental patients were significantly higher than those in normal controls (p = .018). Compared with controls, the positive rates of melanocyte-reactive antibodies were higher in progressive nonsegmental patients and stable nonsegmental patients (p = .032 and p = .046, respectively). Furthermore, we found higher level of IgG4 and lower level of IgM in male than those in female. Higher IgG1 level was also observed in patients with a family history than in those without a family history. In addition, there was a significant inverse correlation between the concentrations of IgG4 and disease duration. Our evaluation about the level of immunoglobulins might provide a useful insight into the pathological process of vitiligo.

Available only for authorised users

Taieb A, Alomar A, Bohm M, Dell’anna ML, De Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5–19. doi:10.1111/j.1365-2133.2012.11197.x.CrossRefPubMed

Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91. doi:10.1016/j.jaad.2010.11.061.CrossRefPubMed

Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90–100.CrossRefPubMed

Valle Y, Lotti TM, Hercogova J, Schwartz RA, Korobko IV. Multidisciplinary approach to R&D in vitiligo, a neglected skin disease. Dermatol Ther. 2012;25(Suppl 1):S1–9. doi:10.1111/dth.12009.CrossRefPubMed

Machadofilho CD, Almeida FA, Proto RS, Landman G. Vitiligo: analysis of grafting versus curettage alone, using melanocyte morphology and reverse transcriptase polymerase chain reaction for tyrosinase mRNA. Sao Paulo Med J. 2005;123(4):187–91. doi:10.1590/S1516-31802005000400006.CrossRef

Narita T, Oiso N, Fukai K, Kabashima K, Kawada A, Suzuki T. Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. Allergol Int. 2011;60(4):505–8. doi:10.2332/allergolint.11-OA-0303.CrossRefPubMed

Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Investig Dermatol. 1991;97(6):1078–80.CrossRefPubMed

Kemp EH, Emhemad S, Akhtar S, Watson PF, Gawkrodger DJ, Weetman AP. Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo. Exp Dermatol. 2011;20(1):35–40. doi:10.1111/j.1600-0625.2010.01181.x.CrossRefPubMed

Takechi Y, Hara I, Naftzger C, Xu Y, Houghton AN. A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res. 1996;2(11):1837–42.PubMed

10.

Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun. 2005;25(Suppl):63–8. doi:10.1016/j.jaut.2005.10.001.CrossRefPubMed

11.

Ingordo V, Gentile C, Iannazzone SS, Cusano F, Naldi L. Vitiligo and autoimmunity: an epidemiological study in a representative sample of young Italian males. J Eur Acad Dermatol Venereol. 2011;25(1):105–9. doi:10.1111/j.1468-3083.2010.03696.x.CrossRefPubMed

12.

Uncu S, Yayli S, Bahadir S, Okten A, Alpay K. Relevance of autoimmune thyroiditis in children and adolescents with vitiligo. Int J Dermatol. 2011;50(2):175–9. doi:10.1111/j.1365-4632.2010.04665.x.CrossRefPubMed

13.

Liu Y, Li J. Preferentially immunoglobulin (IgG) subclasses production in primary Sjogren’s syndrome patients. Clin Chem Lab Med. 2011;. doi:10.1515/CCLM.2011.771.

14.

Lin G, Li J. Elevation of serum IgG subclass concentration in patients with rheumatoid arthritis. Rheumatol Int. 2010;30(6):837–40. doi:10.1007/s00296-009-1330-8.CrossRefPubMed

15.

Taguchi M, Kihara Y, Nagashio Y, Yamamoto M, Otsuki M, Harada M. Decreased production of immunoglobulin M and A in autoimmune pancreatitis. J Gastroenterol. 2009;44(11):1133–9. doi:10.1007/s00535-009-0106-y.CrossRefPubMed

16.

Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol. 2004;4(2):89–99. doi:10.1038/nri1266.CrossRefPubMed

17.

Rahoma SF, Sandhu HK, McDonagh AJ, Gawkrodger DJ, Weetman AP, Kemp EH. Epitopes, avidity and IgG subclasses of tyrosine hydroxylase autoantibodies in vitiligo and alopecia areata patients. Br J Dermatol. 2012;167(1):17–28. doi:10.1111/j.1365-2133.2012.10889.x.CrossRefPubMed

18.

Njoo MD, Das PK, Bos JD, Westerhof W. Association of the Kobner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol. 1999;135(4):407–13.CrossRefPubMed

19.

Alghamdi KM, Kumar A, Taieb A, Ezzedine K. Assessment methods for the evaluation of vitiligo. J Eur Acad Dermatol Venereol. 2012;26(12):1463–71. doi:10.1111/j.1468-3083.2012.04505.x.PubMed

20.

Ali R, Ahsan MS, Azad MA, Ullah MA, Bari W, Islam SN, et al. Immunoglobulin levels of vitiligo patients. Pak J Pharm Sci. 2010;23(1):97–102.PubMed

21.

Santana SS, Silva DA, Vaz LD, Pirovani CP, Barros GB, Lemos EM, et al. Analysis of IgG subclasses (IgG1 and IgG3) to recombinant SAG2A protein from Toxoplasma gondii in sequential serum samples from patients with toxoplasmosis. Immunol Lett. 2012;143(2):193–201. doi:10.1016/j.imlet.2012.02.008.CrossRefPubMed

22.

Zhang H, Li P, Wu D, Xu D, Hou Y, Wang Q, et al. Serum IgG subclasses in autoimmune diseases. Medicine. 2015;94(2):e387. doi:10.1097/MD.0000000000000387.CrossRefPubMedPubMedCentral

23.

Liu Y, Wang W, Li J. Evaluation of serum IgG subclass concentrations in myasthenia gravis patients. Int J Neurosci. 2011;121(10):570–4. doi:10.3109/00207454.2011.596293.CrossRefPubMed

24.

Wang W, Li J. Predominance of IgG1 and IgG3 subclasses of autoantibodies to peptidylarginine deiminase 4 in rheumatoid arthritis. Clin Rheumatol. 2011;30(4):563–7. doi:10.1007/s10067-010-1671-4.CrossRefPubMed

25.

Farboud A, Choy E. Serological investigation of IgG levels and subclasses in rheumatoid arthritis patients following ingestion of bovine type II collagen: results of a double blind, randomised controlled trial. Clin Rheumatol. 2011;30(2):193–9. doi:10.1007/s10067-010-1473-8.CrossRefPubMed

26.

Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716–25. doi:10.1182/blood-2008-09-179754.CrossRefPubMed

27.

Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi:10.3389/fimmu.2014.00520.CrossRefPubMedPubMedCentral

28.

Kapur R, Einarsdottir HK, Vidarsson G. IgG-effector functions: “the good, the bad and the ugly”. Immunol Lett. 2014;160(2):139–44. doi:10.1016/j.imlet.2014.01.015.CrossRefPubMed

29.

Yates NL, Lucas JT, Nolen TL, Vandergrift NA, Soderberg KA, Seaton KE, et al. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. Aids. 2011;25(17):2089–97. doi:10.1097/QAD.0b013e32834b348e.CrossRefPubMedPubMedCentral

30.

Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009;39(4):469–77. doi:10.1111/j.1365-2222.2009.03207.x.CrossRefPubMed

31.

Rayner LE, Hui GK, Gor J, Heenan RK, Dalby PA, Perkins SJ. The Fab conformations in the solution structure of human immunoglobulin G4 (IgG4) restrict access to its Fc region: implications for functional activity. J Biol Chem. 2014;289(30):20740–56. doi:10.1074/jbc.M114.572404.CrossRefPubMedPubMedCentral

32.

Zhu MC, Liu CG, Wang DX, Zhan Z. Detection of serum anti-melanocyte antibodies and identification of related antigens in patients with vitiligo. Genet Mol Res. 2015;14(4):16060–73. doi:10.4238/2015.December.7.19.CrossRefPubMed

33.

Zailaie MZ. Aspirin reduces serum anti-melanocyte antibodies and soluble interleukin-2 receptors in vitiligo patients. Saudi Med J. 2005;26(7):1085–91.PubMed

34.

Kim JY, Do JE, Ahn KJ, Noh S, Jee HJ, Oh SH. Detection of melanocyte autoantigens reacting with autoantibodies in vitiligo patients by proteomics. J Dermatol Sci. 2011;62(3):202–4. doi:10.1016/j.jdermsci.2011.03.004.CrossRefPubMed

35.

Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: patients’ sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Investig Dermatol. 1988;90(6):783–9.CrossRefPubMed

36.

Yu HS, Kao CH, Yu CL. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J Investig Dermatol. 1993;100(6):823–8.CrossRefPubMed

37.

Jordon RE, Xia P, Geoghegan WD. Bullous pemphigoid autoantibodies reactive with intracellular basal keratinocyte antigens: studies of subclass distribution and complement activation. J Clin Immunol. 1992;12(3):163–9.CrossRefPubMed

38.

Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol. 2010;10(8):594–604. doi:10.1038/nri2815.CrossRefPubMed

39.

Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis. 2015;74(1):14–8. doi:10.1136/annrheumdis-2013-204907.CrossRefPubMed

40.

Oxelius VA, Krueger R, Ahlstedt S, Keil T, Lau S, Wahn U. Innate IgG molecules and innate B cells expressed by immunoglobulin constant heavy G chain (Fcgamma) genetic marker genes are involved in the ‘allergic march’ of IgE sensitization in children. Int Arch Allergy Immunol. 2015;166(1):25–9. doi:10.1159/000371351.CrossRefPubMed

41.

March ME, Sleiman PM, Hakonarson H. The genetics of asthma and allergic disorders. Discov Med. 2011;11(56):35–45.PubMed

Title: Evaluation of serum immunoglobulins concentrations and distributions in vitiligo patients
Authors: Yulong Li
Min Yang
Rui Zhang
Wan Liu
Kuo Zhang
Wei Wen
Lang Yi
Qiaoxian Wang
Mingju Hao
Hui Yang
Jianmin Chang
Jinming Li
Publication date: 01-12-2016
Publisher: Springer US
Published in: Immunologic Research / Issue 5-6/2016
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-016-8809-7

At a glance: The STEP trials

Springer Medicine

Evaluation of serum immunoglobulins concentrations and distributions in vitiligo patients

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5-6/2016

HIV infection: focus on the innate immune cells

Variants in LTA, TNF, IL1B and IL10 genes associated with the clinical course of sepsis

Clinical association of mixed connective tissue disease and granulomatosis with polyangiitis: a case report and systematic screening of anti-U1RNP and anti-PR3 auto-antibody double positivity in ten European hospitals

Effect of continuous positive airway pressure (CPAP) therapy on IL-23 in patients with obstructive sleep apnea

Inflammasomes and its importance in viral infections

Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis